Search Results - "Kamura, T"

Refine Results
  1. 1
  2. 2

    Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma by Takemoto, S, Ushijima, K, Kawano, K, Yamaguchi, T, Terada, A, Fujiyoshi, N, Nishio, S, Tsuda, N, Ijichi, M, Kakuma, T, Kage, M, Hori, D, Kamura, T

    Published in British journal of cancer (15-09-2009)
    “…Background: Stat3 is a member of the Janus-activated kinase/STAT signalling pathway. It normally resides in the cytoplasm and can be activated through…”
    Get full text
    Journal Article
  3. 3

    Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: An international collaborative meta-analysis by Kim, H.S, Sardi, J.E, Katsumata, N, Ryu, H.S, Nam, J.H, Chung, H.H, Park, N.H, Song, Y.S, Behtash, N, Kamura, T, Cai, H.B, Kim, J.W

    Published in European journal of surgical oncology (01-02-2013)
    “…Abstract Background The efficacy of neoadjuvant chemotherapy before surgery (NCS) has not been well-established in FIGO stage IB1 to IIA cervical cancer when…”
    Get full text
    Journal Article
  4. 4

    Rbx1, a Component of the VHL Tumor Suppressor Complex and SCF Ubiquitin Ligase by Kamura, T., Koepp, D. M., Conrad, M. N., Skowyra, D., Moreland, R. J., Iliopoulos, O., Lane, W. S., Kaelin, W. G., Elledge, S. J., Conaway, R. C., Harper, J. W., Conaway, J. W.

    “…The von Hippel-Lindau (VHL) tumor suppressor gene is mutated in most human kidney cancers. The VHL protein is part of a complex that includes Elongin B,…”
    Get full text
    Journal Article
  5. 5

    The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2 by Kamura, T, Conrad, M N, Yan, Q, Conaway, R C, Conaway, J W

    Published in Genes & development (15-11-1999)
    “…The RING-H2 finger protein Rbx1 is a subunit of the related SCF (Skp1-Cdc53/Cul1-F-box protein) and von Hippel-Lindau (VHL) tumor suppressor (elongin…”
    Get full text
    Journal Article
  6. 6

    A Consensus-based Guideline Defining the Clinical Target Volume for Pelvic Lymph Nodes in External Beam Radiotherapy for Uterine Cervical Cancer by Toita, Takafumi, Ohno, Tatsuya, Kaneyasu, Yuko, Uno, Takashi, Yoshimura, Ryouichi, Kodaira, Takeshi, Furutani, Kazuhisa, Kasuya, Goro, Ishikura, Satoshi, Kamura, Toshiharu, Hiraoka, Masahiro

    Published in Japanese journal of clinical oncology (01-05-2010)
    “…Objective To develop a consensus-based guideline as well as an atlas defining pelvic nodal clinical target volumes in external beam radiotherapy for uterine…”
    Get full text
    Journal Article Conference Proceeding
  7. 7
  8. 8

    Dynamics of placental ghrelin production and its receptor expression in a Dahl salt-sensitive rat model of intrauterine growth restriction by Nonoshita, A, Nishi, Y, Takushima, S, Oshima, M, Hosoda, H, Kangawa, K, Kojima, M, Mifune, H, Tanaka, E, Hori, D, Kamura, T

    Published in Placenta (Eastbourne) (01-05-2010)
    “…Abstract Background Ghrelin, a peptide hormone produced mainly in the stomach, is an endogenous ligand for the growth hormone secretagogue receptor (GHS-R)…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13

    Cytological nuclear atypia classification can predict prognosis in patients with endometrial cancer by Yamaguchi, T., Kawahara, A., Hattori, S., Taira, T., Abe, H., Sanada, S., Akiba, J., Nishio, S., Ushijima, K., Kamura, T., Kage, M.

    Published in Cytopathology (Oxford) (01-06-2015)
    “…Objective Endometrial cancer is one of the leading causes of malignancy in females. Nuclear findings are important for patients with cancer, and can provide…”
    Get full text
    Journal Article
  14. 14
  15. 15
  16. 16

    The History of the Gynecologic Cancer Study Group (GCSG) of the Japan Clinical Oncology Group (JCOG) by Onda, Takashi, Konishi, Ikuo, Yoshikawa, Hiroyuki, Kamura, Toshiharu

    Published in Japanese journal of clinical oncology (01-10-2011)
    “…The Gynecologic Cancer Study Group (GCSG) of the Japan Clinical Oncology Group (JCOG) was organized in 1994. The GCSG has developed under the leadership of…”
    Get full text
    Journal Article
  17. 17

    Co-expression of Y box-binding protein-1 and P-glycoprotein as a prognostic marker for survival in epithelial ovarian cancer by Huang, Xiao, Ushijima, Kimio, Komai, Kan, Takemoto, Yumi, Motoshima, Shigenobu, Kamura, Toshiharu, Kohno, Kimitoshi

    Published in Gynecologic oncology (01-05-2004)
    “…Objectives. This study aimed to observe the expressions of Y box-binding protein-1 (YB-1) and P-glycoprotein (P-gp) in primary ovarian tumor and to determine…”
    Get full text
    Journal Article
  18. 18

    UDP-Gal: βGlcNAc β1, 3-galactosyltransferase, polypeptide 3 (GALT3) is a tumour antigen recognised by HLA-A2-restricted cytotoxic T lymphocytes from patients with brain tumour by TSUDA, N, NONAKA, Y, SHICHIJO, S, YAMADA, A, ITO, M, MAEDA, Y, HARADA, M, KAMURA, T, ITOH, K

    Published in British journal of cancer (21-10-2002)
    “…Patient prognosis in the case of malignant brain tumours is generally poor, despite significant improvements in the early detection of the tumours, and thus…”
    Get full text
    Journal Article
  19. 19

    Detection of peptide-specific CTL-precursors in peripheral blood lymphocytes of cancer patients by Maeda, Y, Hida, N, Niiya, F, Katagiri, K, Harada, M, Yamana, H, Kamura, T, Takahashi, M, Sato, Y, Todo, S, Itoh, K

    Published in British journal of cancer (23-09-2002)
    “…Development of therapeutic vaccines is one of the major areas of tumour immunotherapy today. However, clinical trials of peptide-based cancer vaccines have…”
    Get full text
    Journal Article
  20. 20

    Tumor-associated antigen 22-1-1 expression in the uterine cervical squamous neoplasias by SONODA, K, KAKU, T, KAMURA, T, NAKASHIMA, M, WATANABE, T, NAKANO, H

    Published in Clinical cancer research (01-06-1998)
    “…We have reported that a novel tumor-associated antigen (Ag), 22-1-1, was expressed in cancer cells derived mainly from the uterus and ovary [K. Sonoda et al.,…”
    Get full text
    Journal Article